Takeda Defeats Motion to Dismiss Patent and Contract Claims

Haug Partners LLP
Contact

On September 9, 2020, Judge Richard G. Andrews of the United States District Court for the District of Delaware ruled in favor of Takeda Pharmaceuticals U.S.A., Inc. in the case Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc. (No. 1:19-cv-02216-RGA). Takeda’s complaint asserts breach of contract, alleging that Mylan’s launch and sale of its generic colchicine product is in breach of a settlement and license agreement that the parties entered into to settle an earlier Hatch-Waxman litigation, and also asserts that Mylan’s activities constitute infringement of Takeda’s patents. Mylan filed a motion to dismiss Takeda’s complaint, which Takeda opposed on a variety of grounds. Judge Andrews denied Mylan’s motion to dismiss, clearing the way for the case to proceed to discovery.

Takeda was represented by Haug Partners attorneys Edgar H. Haug, Porter F. Fleming, Jonathan A. Herstoff, and Camille Y. Turner.

Written by:

Haug Partners LLP
Contact
more
less

Haug Partners LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.